Ebola: DRC at the Center of an International Clinical Trial for New Treatments
A New Step Forward in the Fight Against Ebola
The World Health Organization (WHO) has announced the imminent launch of a clinical trial in the Democratic Republic of Congo to evaluate new treatments against the Bundibugyo strain of the Ebola virus disease. With preparations now completed, the first trials are expected to begin as early as next week.
Two Antivirals Under Study
Researchers will evaluate two candidate molecules: MBP134 and remdesivir. These will be tested separately and then in combination in order to measure their ability to reduce mortality and improve the chances of survival for infected patients.
International Scientific Cooperation
The study is being conducted by a consortium bringing together the Democratic Republic of Congo’s National Institute for Biomedical Research (INRB), the NGO ALIMA, the University of Oxford and the WHO. The United States and the pharmaceutical company Gilead Sciences have provided the doses needed to carry out the trials.
Heightened Vigilance Beyond Borders
This announcement comes as French authorities have reported the detection of a case of Ebola virus disease in a humanitarian doctor who recently returned from a mission in the DRC. According to the French Ministry of Health, the patient was admitted to a specialized facility and placed in isolation in a highly secure unit. Authorities say that all biosafety measures have been applied to prevent any risk of transmission.
Communities at the Heart of the Process
According to WHO Director-General Tedros Adhanom Ghebreyesus, the affected communities will be fully involved in the conduct of the clinical trial. The organization intends to ensure that they are informed and engaged throughout the process.
The WHO chief also stated that affected communities will be able to access the treatments if they prove to be safe and effective. This is a hopeful prospect for the DRC, which remains one of the most experienced countries in the fight against Ebola.
Hope for the Health Response
Beyond scientific research, this trial represents a major opportunity to strengthen response capacities in the face of future outbreaks. The expected results could contribute to the emergence of new therapeutic strategies and sustainably improve the care of patients affected by the Ebola virus.
By Héritier Maila
About The Author
